Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Lung cancer represents one of the most common neoplasms and the main cause of cancer‑
associated death worldwide. Its relationship with different risk factors such as tobacco, which …

PURPOSE Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) …

Radiogenomic and radiotranscriptomic studies have the potential to pave the way for a
holistic decision support system built on genomics, transcriptomics, radiomics, deep features …

Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has
undergone rapid changes with innovations in oncogene-directed therapy and immune …

Molecular biomarker testing is the standard of care for non–small cell lung cancer (NSCLC)
patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean …

Lung cancer is the world's leading cause of cancer-related deaths. Epidermal growth factor
receptor (EGFR) is one of the critical oncogenes and plays a significant role in tumor …

Emerging studies have reported the potential anticancer activity of benzimidazole-based
anthelmintics (BBA) against lung cancer (LC). However, mechanism underlying the …

Epidermal growth factor receptor (EGFR) is one of the most well-studied oncogenes with
roles in proliferation, growth, metastasis, and therapeutic resistance. This intense study has …

Non-small cell lung cancer (NSCLC) is the most frequent form of lung cancer and represents
a set of histological entities that have an ominous long-term prognosis, for example …